List view / Grid view

Ellen Capon (Drug Target Review)

 

article

The evolution of cell therapy to address unmet medical needs

19 June 2024 | By ,

We had the privilege of interviewing Brian Culley, CEO of Lineage Cell Therapeutics. He discusses how Lineage’s pluripotent stem cell platform is extraordinarily advantageous, details two early-stage programmes addressing auditory and vision disorders and reveals how Lineage is choosing to target conditions that will make a real difference.

article

Tessera Therapeutics: addressing Alpha-1 Antitrypsin Deficiency

18 June 2024 | By ,

As the industry looks beyond CRISPR to safely introduce therapeutic genomic changes anywhere in the body, in vivo gene editing holds immense potential to address diseases with a genetic basis. Boston-based biotech Tessera Therapeutics is pioneering the next generation of genetic medicines with its Gene Writing™ platform. At this year’s…